BA
PTCT icon

Boston Advisors’s PTC Therapeutics PTCT Stock Holding History

Boston Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$1.31M Buy
38,641
+11,479
+42% +$500K 0.07% 345
2019
Q2 		$1.22M Sell
27,162
-213
-0.8% -$8.41K 0.07% 315
2019
Q1 		$1.03M Hold
27,375
– – 0.05% 337
2018
Q4 		$940K Buy
27,375
+2,285
+9% +$82.2K 0.05% 324
2018
Q3 		$1.18M Sell
25,090
-8
-0% -$331 0.05% 349
2018
Q2 		$847K Buy
+25,098
New +$783K 0.02% 413

Other funds holding PTCT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Boston Advisors's PTCT Position: Q3 2019 in Review

Boston Advisors increased its PTC Therapeutics (PTCT) stake by 42% in Q3 2019, buying an estimated $500K and bringing the position to 38,641 shares worth $1.31M. The position accounts for 0.07% of the portfolio, ranked #345.

Boston Advisors first reported a position in PTCT in Q2 2018 and has held it in 6 quarters since. 184 funds tracked by Wall St. Rank hold PTCT as of Q3 2019.

  • Boston Advisors held 38,641 shares of PTC Therapeutics worth $1.31M as of Q3 2019.
  • Boston Advisors bought 11,479 PTC Therapeutics shares in Q3 2019, an estimated $500K.
  • PTC Therapeutics made up 0.07% of Boston Advisors's portfolio in Q3 2019, its #345 holding.
  • Boston Advisors first reported a position in PTC Therapeutics in Q2 2018 and has held it in 6 quarters since.
  • 184 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2019.

Based on Boston Advisors's 13F filing for Q3 2019, filed 5 Nov 2019.